Results 201 to 210 of about 233,740 (307)

Distinct Gene Expression Profiles of Ara h 2‐Specific B Cells in Desensitization and Tolerance During Peanut Oral Immunotherapy

Allergy, EarlyView.
Gene expression of Ara h 2‐specific B cells over the course of the peanut OIT. Isotype of allergen‐specific B cells changes through OIT towards IgG4. Peanut OIT changes the gene expression of allergen‐specific memory B cells. OIT patients showed increased gene expression for regulatory B cells and immune regulation.
Stephan R. Schneider, Juan‐Felipe López, Huseyn Babayev, Willem van de Veen, Minglin Yang, Cezmi A. Akdis, Kari Nadeau, Carolyn H. Baloh, Stacie M. Jones, Lisa M. Wheatley, Mübeccel Akdis, IMPACT, Amy M. Scurlock, D. Pesek, Joy Laurienzo‐Panza, Marshall Plaut, A. Wesley Burks, Edwin H. Kim, Mike Kulis, Anna Nowak‐Wegrzyn, Hugh A. Sampson, Julie Wang, Robert A. Wood, Sharon Chinthrajah, Robert Sayantani B. Sindher, Jacqueline Johnson, Katharine Spain, Denise C. Babineau, Hyunsook Chin, Rachel Yan, Don Whitehouse, Michelle L. Sever, Srinath Sanda, David Larson, Tielin Qin, Gina Marchesini, Kavitha Gilroy, Sylvia Posso, Sabrina Skiba, Thien‐Son Nguyen, Adam Wojno, Tuan Nguyen, Vivian Gersuk, Quynh‐Anh Nguyen, Jessica Garber, Kimberly O'Brien, Brandon Larson, C. Cousens‐Jacobs, Alex Hu   +48 more
wiley   +1 more source

Chimeric antigen receptor T-cell therapy in systemic lupus erythematosus: From B cell depletion to immune reprogramming. [PDF]

J Transl Autoimmun
Zhao W, Chen M, Long J, Lu P, Jin J.
europepmc   +1 more source

Failed Mucosal Allostasis Distinguishes Murine IgG‐ From IgE‐Mediated Recurrent Severe Anaphylaxis

Allergy, EarlyView.
This study investigates IgE‐ and IgG‐mediated pathways in acute and recurrent anaphylaxis using a murine ASA‐PSA model, assessing barrier integrity, immune activation and tissue remodelling across pulmonary and intestinal compartments. Recurrent IgE‐ and IgG‐mediated anaphylaxis produces divergent mucosal outcomes despite comparable systemic severity ...
Abdurrahman Simsek, Muhammed Ali Kizmaz, Tugce Bozkurt, Sude Toprakkaz, Mehmet Emre Topcu, Musa Ozgur Ozyigit, Ahmet Akkoc, Dane Ediger, Ferah Budak Sener   +8 more
wiley   +1 more source

Mechanisms, optimization strategies, and salvage options for CAR-T cell therapy. [PDF]

Biomark Res
Wu B, Wang J, Zou Q, Cai J, Zhang Y, Zhong Q, Bai B, Liu F, Cao Y, Li P, Dai DL, Cai Q.   +11 more
europepmc   +1 more source

Mesenchymal Stem Cells From a Klinefelter Syndrome Patient: Functional Characterization and Therapeutic Implications

Andrology, EarlyView.
ABSTRACT Background Cell therapy, particularly those utilizing mesenchymal stem/stromal cells (MSCs), is gaining traction as a therapeutic option for regenerative treatment in patients with limited therapeutic options. Although the safety of MSC‐based interventions is well established, uncertainties remain regarding how genetic abnormalities and ...
Marzena Zychowicz, Wioletta Lech, Anna Figiel‐Dabrowska, Marta Kot, Magdalena Murzyn, Natalia Malawska, Barbara Pienkowska‐Grela, Zuzanna Sandowska‐Markiewicz, Iwona Ziolkowska‐Suchanek, Agnieszka Zimna, Tomasz Oldak, Natalia Rozwadowska, Anna Sarnowska   +12 more
wiley   +1 more source

CAR T cells against the B cell receptor to precisely eliminate pathogenic B cells. [PDF]

Mol Ther Oncol
Bochi-Layec AC, Cohen IJ, Lemoine J, Ruella M.   +3 more
europepmc   +1 more source

A Personalised Vaccination Program Based on Immune Reconstitution in Paediatric Cancer Survivors

Acta Paediatrica, EarlyView.
ABSTRACT Aims Paediatric cancer survivors often experience treatment‐induced immunosuppression, requiring post‐treatment revaccination. However, immune recovery timelines vary, and current revaccination guidelines, largely based on data of varied quality derived from studies on acute‐lymphoblastic‐leukaemia (ALL), may not be applicable across all ...
Menucha Jurkowicz, Raz Somech, Dan Dominissini, Nathan Keller, Efrat Dresner, Michal Paret, Gilad Sherman, Guy Katzenellenbogen, Elina Gelman, Keren Asraf, Ram Doolman, Atar Lev, Amos J. Simon, Helly Vernitsky, Assaf Barg, Hana Golan, Amos Toren, Michal Stein   +17 more
wiley   +1 more source

B7 homolog 3-targeted CAR-T cells secreting EGFR T-cell engagers for improved control of glioblastoma progression. [PDF]

Mol Biomed
Zhang Z, Yang N, Zeng H, Chen Y, Lu H, Xu L, Wang Z, Wang G, Zhou L, Tong A.   +9 more
europepmc   +1 more source

Increased anergic B cells and decreased antibody‐secreting cells during romiplostim treatment in patients with immune thrombocytopenia

British Journal of Haematology, EarlyView.
Summary Patients with immune thrombocytopenia (ITP) exhibit substantial heterogeneity in treatment responses. Approximately 30%–50% of patients maintain remission after discontinuation of thrombopoietin receptor agonists (TPO‐RA), suggesting immunomodulatory effects beyond enhanced thrombopoiesis.
Vivianne S. Nelson, Rebeca Gutiérrez‐Cózar, Rebecca Cornelis, S. Marieke van Ham, Anja ten Brinke, Rick Kapur   +5 more
wiley   +1 more source

Overcoming fratricide of CD86 targeting CAR-T cells by defined logic-gate CAR strategy. [PDF]

Exp Hematol Oncol
Riet T, Lennartz S, Bösing N, Prinz LF, Dähn L, Scheid C, Hallek M, Chmielewski MM.   +7 more
europepmc   +1 more source